Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.40 |
| ▸ | MMP13 | P45452 | 13/20 | 0.39 |
| ▸ | MMP2 | P08253 | 5/20 | 0.39 |
| ▸ | MMP1 | P03956 | 3/20 | 0.39 |
| ▸ | MMP9 | P14780 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000707 | 0.89 | PTPN2 (0.81) | PTPN2PTPN1ALOX5MMP13MMP2 | |
| SCHEMBL6000753 | 0.88 | PTPN2 (0.79) | PTPN2PTPN1ALOX5MMP13MMP2 | |
| SCHEMBL6000799 | 0.88 | PTPN1 (0.79) | PTPN2PTPN1MMP13MMP2MMP1 | |
| SCHEMBL6001017 | 0.87 | PTPN2 (0.76) | PTPN2PTPN1ALOX5MMP13MMP2 | |
| SCHEMBL5999110 | 0.87 | PTPN2 (0.76) | PTPN2PTPN1ALOX5MMP13MMP2 | |
| SCHEMBL6000062 | 0.87 | PTPN2 (0.76) | PTPN2PTPN1ALOX5MMP13MMP2 | |
| SCHEMBL6000222 | 0.86 | PTPN1 (0.76) | PTPN2PTPN1MMP13MMP2MMP1 | |
| SCHEMBL6000783 | 0.85 | PTPN2 (0.75) | PTPN2PTPN1ALOX5MMP13MMP2 | |
| SCHEMBL5999202 | 0.83 | PTPN2 (0.71) | PTPN2PTPN1ALOX5MMP13MMP2 | |
| SCHEMBL6000857 | 0.83 | PTPN2 (0.71) | PTPN2PTPN1ALOX5MMP13MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | claimed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | claimed |
| US-20260146032-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2026-05-28 | — | — | US | disclosed |
| US-20250333390-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2025-10-30 | — | — | US | disclosed |
| US-20250326728-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2025-10-23 | — | — | US | disclosed |
| EP-4347575-B1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2025-07-23 | — | — | EP | disclosed |
| US-12365658-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2025-07-22 | — | — | US | disclosed |
| EP-4551562-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | Albireo AB (SE) | 2025-05-14 | — | — | EP | disclosed |
| CN-119977993-A | Solid forms of thienopyrimidinedione ACC inhibitors and methods of making the same | 吉利德阿波罗公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-114269745-B | Heteroaryl substituted pyrazolopyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | 海帕瑞吉尼克斯股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| CN-114269745-A | Heteroaryl substituted pyrazolopyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | 海帕瑞吉尼克斯股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-11279710-B2 | Processes for preparing ACC inhibitors and solid forms thereof | GILEAD SCIENCES, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-11267794-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2022-03-08 | — | — | US | disclosed |
| US-20220064181-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | GILEAD APOLLO, LLC | 2022-03-03 | — | — | US | disclosed |
| US-20220041567-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2022-02-10 | — | — | US | disclosed |
| WO-2022029101-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2022-02-10 | — | — | WO | disclosed |
| US-20220041568-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2022-02-10 | — | — | US | disclosed |
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1553091-A1 | HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267794-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | PTPN2 1919/4885PTPN1 1776/4885ALOX5 1094/4885 |
| US-20060122181-A1 | Heteroaromatic pentacyclic compound and medicinal use thereof | PTPN11, PTPN1, PTPN3 | PTPN2 11/4885PTPN1 2/4885ALOX5 1693/4885 |
| US-20250333390-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | PTPN2 1972/4885PTPN1 1730/4885ALOX5 931/4885 |
| US-20220041568-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | PTPN2 1974/4885PTPN1 1707/4885ALOX5 930/4885 |
| US-20250326728-A1 | BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | PTPN2 2571/4885PTPN1 2706/4885ALOX5 1083/4885 |
| US-11279710-B2 | Processes for preparing ACC inhibitors and solid forms thereof | ACACA, ACACB, ACAT2 | PTPN2 3988/4885PTPN1 3481/4885ALOX5 1500/4885 |
| US-20220064181-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | ACACA, ACACB, COASY | PTPN2 3678/4885PTPN1 3458/4885ALOX5 504/4885 |
| US-12365658-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | PTPN2 1972/4885PTPN1 1730/4885ALOX5 931/4885 |
| US-20220041567-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | PTPN2 1919/4885PTPN1 1776/4885ALOX5 1094/4885 |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | PTPN2 1441/4885PTPN1 1272/4885ALOX5 4021/4885 |
| US-20260146032-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A2, SLC10A1, SLC5A2 | PTPN2 1455/4885PTPN1 1926/4885ALOX5 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.